【摘要】 目的探讨盐酸舍曲林与艾司西酞普兰治疗急性脑梗死后抑郁的临床疗效及安全性。方法选取2017年1月至2019年1月我院收治的急性脑梗死后抑郁患者96例,随机分为两组各48例。对照组采用草酸艾司西酞普兰片治疗,观察组采用草酸艾司西酞普兰片联合盐酸舍曲林片治疗,服药周期均为10周。治疗10周后对比两组患者的SAS、 SDS、 NIHSS评分及不良反应发生情况。结果治疗10周后,观察组的治疗总有效率为91.67%,高于对照组的75.00%(P <0.05);观察组的SAS、 SDS及NIHSS评分均低于对照组(P <0.05);观察组的不良反应发生率为10.42%,低于对照组的27.08%(P <0.05)。结论盐酸舍曲林与艾司西酞普兰治疗急性脑梗死后抑郁效果明显,能够提高临床疗效,减少不良反应,减轻负性情绪及神经缺损程度,提高服药安全性,值得临床推广应用。更多还原

【Abstract】 Objective To explore the clinical efficacy and safety of sertraline hydrochloride and escitalopram in the treatment of depression after acute cerebral infarction. Methods 96 patients with depression after acute cerebral infarction admitted to our hospital from January 2017 to January 2019 were selected and randomly divided into two groups, with 48 cases in each group. The control group was treated with escitalopram oxalate tablets, and the observation group was treated with escitalopram oxalate tablets combined with sertraline hydrochloride tablets. Both groups were treated for 10 weeks. After 10 weeks of treatment, the SAS, SDS and NIHSS scores, and the adverse reactions were compared between the two groups. Results After 10 weeks of treatment, the total effective rate of treatment in the observation group was 91.67%, higher than 75.00% in the control group(P <0.05). The SAS, SDS and NIHSS scores of the observation group were lower than those of the control group(P <0.05). The incidence of adverse reactions in the observation group was 10.42%, lower than 27.08% in the control group(P <0.05). Conclusions Sertraline hydrochloride and escitalopram in the treatment of depression after acute cerebral infarction has significant effect, can improve the clinical efficacy, reduce the adverse reactions, relieve the negative emotions and nerve defect degree, and improve the safety of medication, which is worthy of clinica promotion and application.更多还原